Clinically, these findings support the broad integration of SGLT2 inhibitors into HF management, including in populations underrepresented in earlier trials, and provide quantitative estimates that can inform individualized risk-benefit discussions in daily practice. The gene discussed is SLC5A2; the disease is hydrops fetalis.